Bronstein, Gewirtz & Grossman LLC Urges GRAIL, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

Bronstein, Gewirtz & Grossman, LLC, a nationally recognized investor-rights law firm, announces that a class action lawsuit has been filed against GRAIL, Inc. (NASDAQ: GRAL) and certain of its officers. This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwise acquired Grail securities between May 13, 2025 and February 19, 2026, both dates inclusive (the "Class Period"). Such investors are encouraged to join this case by visiting the firm's site: bgandg.com/GRAL . Grail Case Details The Complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements and/or failed to disclose that: Defendants misrepresented the likelihood of achieving the primary endpoint of a statistically significant reduction in Stage III-IV cancers in Grail's NHS-Galleri trial, creating the false impression that they possessed reliable information supporting such outcome while concealing adverse facts that diminished that possibility; Defendants' optimism regarding the NHS-Galleri study's prospects was overstated and lacked a reasonable basis; and Defendants' confidence based on purportedly 'Positive Top-Line Results' and prior studies was misleading, as it ignored emerging data trends and other information suggesting that the trial's three-year timeframe was insufficient to demonstrate achievement of the primary endpoint, rendering Defendants' statements about the Company's business, operations, and prospects materially false and misleading at all relevant times. What's Next for Grail Investors? A class action lawsuit has already been filed. If you wish to review a copy of the Complaint, you can visit the firm's site: bgandg.com/GRAL , or you may contact Peretz Bronstein, Esq. or his Client Relations Manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at ...